High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.
about
Recent developments in immunotherapy of acute myeloid leukemia.Recent advances in T-cell immunotherapy for haematological malignancies.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.Practical considerations for chimeric antigen receptor design and delivery.Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.Advances in immunotherapy for pediatric acute myeloid leukemia.Treating hematological malignancies with cell therapy: where are we now?Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy.Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple MyelomaEfficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
P2860
Q38661895-45C1BA69-1BB5-49DA-AE61-5B55CE979791Q38789518-F4595520-744D-4125-AA4D-0CB0DF108CA2Q38830813-CFF27511-6D2B-4E41-8E14-E01A465CC6EEQ38933510-04693E3F-028B-4E33-89C0-54F7A04B7588Q38951943-B5EC4F2D-0711-4380-BC47-F21C23101F26Q40135347-8D8E1F19-8D43-4147-877C-732E9D8ED181Q41432593-4CFEBA26-75C0-4080-B4F3-4DAAE5657AE5Q45868559-98545048-760D-4A4C-8AB5-A0A759897ED5Q47436657-97B7BB1B-2E77-4576-8FCD-65A163373C18Q47930962-BE62E0D0-22ED-4F62-B678-5C65FEE5D822Q48640926-76A242AE-73AF-41CE-9A1A-8874E9A14F73Q49843670-3A68225F-7B56-482A-BAE2-B9AF6EE2CB3CQ50025535-DEE6B1F2-E7D9-4163-A62E-9A37026E6295Q52560709-5F53BC6D-B36D-4120-9F39-AC37FFE36BDDQ54979939-E35EA684-6963-468B-AD55-36D9D51C3564Q56966447-EC821E41-3870-4A97-8041-F78DE595DCDAQ59125585-BE15F47F-5E54-4F9B-8D74-8CEA3FAA9FCC
P2860
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
High-affinity FRβ-specific CAR ...... lineage without HSC toxicity.
@en
type
label
High-affinity FRβ-specific CAR ...... lineage without HSC toxicity.
@en
prefLabel
High-affinity FRβ-specific CAR ...... lineage without HSC toxicity.
@en
P2093
P2860
P356
P1433
P1476
High-affinity FRβ-specific CAR ...... lineage without HSC toxicity.
@en
P2093
D J Powell
D S Dimitrov
K Schutsky
P2860
P2888
P304
P356
10.1038/LEU.2016.35
P577
2016-02-22T00:00:00Z
P6179
1002265610